ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1587

Predictors of Body Mass Index in an Early Systemic Sclerosis Cohort

Ali Ayla1, Meng Zhang1, Claudia Pedroza2, Bingrui Chen2, Brian Skaug1, Maureen Mayes1, Shervin Assassi1 and Zsuzsanna McMahan1, 1UTHealth Houston Division of Rheumatology, Houston, TX, 2UTHealth Houston, Houston, TX

Meeting: ACR Convergence 2024

Keywords: Scleroderma, Systemic sclerosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 17, 2024

Title: Systemic Sclerosis & Related Disorders – Clinical Poster II

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: Malnutrition is a significant problem among patients with systemic sclerosis (SSc). Body mass index (BMI) is often low in patients with malnutrition. Low BMI is associated with mortality in patients with SSc, yet the predictors of a low BMI are unknown. Here, we sought to identify baseline predictors of low BMI over time in SSc.

Methods: SSc patients enrolled in our large, well-characterized prospective cohort, who fulfilled the 2013 ACR/European League Against Rheumatism criteria and had a disease duration of less than five years from the first non-Raynaud’s symptom onset at enrollment, were studied. The patients were followed semi-annually during the first three years of enrollment and annually thereafter. Linear mixed-effects model was utilized to assess the relationship between baseline demographic and clinical variables and serial BMI measurements. Variability in BMI was modeled as a random intercept and variability in the change of BMI over time as a random slope. The baseline predictors from the univariable analyses and potential known confounders of BMI were utilized to construct multivariable models.

Results: Among 450 patients with 2723 BMI measurements, the mean (SD) follow-up time was 5.3 (4.8) years. Univariable analyses demonstrated that younger age (b= 0.06, 95% CI 0.02, 0.10, P = 0.03), pseudo-obstruction (b= -6.1, 95% CI -11.4, -0.8, P = 0.03), higher vascular Medsger Severity score (b= -2.11, 95% CI -3.18, -1.03, P < 0.001), and higher cardiac Medsger Severity score (b= -2.70, 95% CI -5.37, -0.02, P = 0.049) predicted the development of a lower BMI. Interestingly, smaller oral aperture also predicted lower BMI (b=1.02, 95% CI 0.49, 1.56, P < 0.001). In contrast, the presence of anti-centromere antibody (b=1.69, 95% CI 0.12, 3.26, P = 0.04) predicted higher BMI over time. The time trend for BMI was negative but non-significant (b=-0.043, 95% CI -0.11, 0.03, P = 0.23). Multivariable models confirmed that age, size of oral aperture, pseudo-obstruction, and Medsger Vascular Severity scores remained significant predictors of BMI. 

Conclusion: Distinct clinical features, including pseudo-obstruction and vascular severity, predict lower BMI, which is associated with a worse prognosis in SSc. These predictors may enhance patient risk stratification, identify patients who may benefit from targeted nutritional therapies, and identify novel targets for SSc GI disease.

Supporting image 1

Table 1. Patient characteristics at baseline.

Supporting image 2

Table 2. Multivariable model predicting longitudinal BMI measurements.

Supporting image 3

Figure 1. Trajectory of BMI over time.


Disclosures: A. Ayla: None; M. Zhang: None; C. Pedroza: None; B. Chen: None; B. Skaug: None; M. Mayes: AstraZeneca, 5, Atyr, 5, Boehringer-Ingelheim, 1, 5, Horizon Therapeutics, 5, Merck/MSD, 5; S. Assassi: AstraZeneca, 2, aTyr, 2, 5, BMS, 2, Boehringer-Ingelheim, 2, 5, CSL Behring, 2, Janssen, 5, Merck/MSD, 2, TeneoFour, 2; Z. McMahan: Boehringer-Ingelheim, 2.

To cite this abstract in AMA style:

Ayla A, Zhang M, Pedroza C, Chen B, Skaug B, Mayes M, Assassi S, McMahan Z. Predictors of Body Mass Index in an Early Systemic Sclerosis Cohort [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/predictors-of-body-mass-index-in-an-early-systemic-sclerosis-cohort/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/predictors-of-body-mass-index-in-an-early-systemic-sclerosis-cohort/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology